Pricing Log in Create free account
Friday 6 November 2026 Export PTGX’s income statement to Excel — free account

Protagonist Therapeutics, Inc.

PTGX Healthcare Biotechnology

Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.

Revenue
+3,749.2%
EPS
+549.1%
Free cash flow
+839.7%

Quarter to June 2026, against a year earlier

131.81 3.45 −2.55%
Market cap
$8.8B
P/E
108×
Fwd P/E
31.2×
Dividend yield
—
F-score
4/9
Altman Z
61.55
Beneish M
−7.18
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Protagonist Therapeutics, Inc. 10-K filed Feb 25, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:28 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 21, 2025: 82 added · 101 removed · 68 modified

  1. Removed · OVERVIEW

    We are a discovery through late-stage development biopharmaceutical company focused on peptide therapeutics. Our clinical programs fall into two broad categories of diseases: (i) hematology and blood disorders, and (ii) inflammatory and immunomodulatory (“I&I”) diseases. Two novel peptides derived from our proprietary discovery technology platform, rusfertide and icotrokinra (formerly known as JNJ-2113), are currently in advanced Phase 3 clinical development, with New Drug Application (“NDA”) submissions to the U.S. Food and Drug Administration (“FDA”) potentially in 2025.